Results from a blind and a non-blind randomised trial run in parallel: experience from the Estonian Postmenopausal Hormone Therapy (EPHT) Trial

Table 4 Crude hazard ratios for different outcome events among recruited women in blind versus non-blind trial arms, EPHT Trial: data presented for the periods from 2001 to 2004 and from 2001 to 2007

Outcome/ Time period	Recruited women			Non-recruited women
	Blind vs non-blind HT, HR (95% CI)	Placebo vs non-treatment, HR (95% CI)	Blind vs non-blind trial, HR (95% CI)*	Blind vs non- blind trial, HR (95% CI)
Coronary heart disease
2001-2004	0.89 (0.66-1.19)	0.75 (0.55-1.02)	0.82 (0.66-1.01)	1.06 (0.89-1.26)
2001-2007	0.77 (0.60-1.00)	0.78 (0.60-1.01)	0.77 (0.64-0.93)	1.01 (0.87-1.18)
Cancer
2001-2004	0.59 (0.29-1.23)	0.47 (0.21-1.04)	0.53 (0.31-0.91)	0.94 (0.66-1.33)
2001-2007	0.77 (0.44-1.33)	1.23 (0.68-2.23)	0.95 (0.64-1.42)	0.90 (0.65-1.24)
Cerebrovascular disease
2001-2004	0.80 (0.48-1.33)	0.34 (0.18-0.67)	0.57 (0.38-0.84)	1.24 (0.92-1.68)
2001-2007	0.80 (0.52-1.24)	0.51 (0.30-0.86)	0.66 (0.47-0.92)	1.15 (0.90-1.46)
Bone fractures
2001-2004	0.69 (0.43-1.10)	0.94 (0.65-1.37)	0.83 (0.62-1.11)	1.10 (0.87-1.38)
2001-2007	0.96 (0.69-1.35)	0.90 (0.67-1.21)	0.93 (0.74-1.16)	1.17 (0.97-1.42)
Total mortality
2001-2004	0.73 (0.18-3.07)	0.27 (0.03-2.32)	0.51 (0.16-1.63)	0.90 (0.52-1.67)
2001-2007	1.22 (0.49-3.08)	0.86 (0.33-2.22)	1.03 (0.53-1.98)	1.02 (0.69-1.52)
All outcomes combined
2001-2004	0.81 (0.65-1.02)	0.75 (0.59-0.93)	0.78 (0.66-0.91)	1.10 (0.97-1.25)
2001-2007	0.83 (0.69-1.02)	0.81 (0.67-0.98)	0.82 (0.72-0.94)	1.08 (0.97-1.21)

ISSN: 1471-2288